TAmiRNA will spotlight its miND® NextGen small RNA-sequencing platform and the hepatomiR® test—Europe's first CE-IVD marked test for liver function microRNA biomarkers—at the Zürich conference. These innovations highlight TAmiRNA's strengths in microRNA diagnostic development. Dr. Matthias Hackl, CEO and Chief Scientific Officer, will present "MicroRNAs as a Novel Class of Biomarkers" on Friday, September 6, in Session 6: New Technologies. He will discuss the critical role of miRNA biomarkers and TAmiRNA's advanced sequencing techniques, which speed up the discovery of novel biomarker associations. Don’t miss this opportunity to explore TAmiRNA's latest advancements in microRNA diagnostics. Reach out to Matthias directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA [...]

TAmiRNA CEO/CSO Matthias Hackl and scientst Marianne Pultar will attend the SelectBIO Congress Rotterdam next week and will showcase its services at Booth E5 in the Exhibition Zone at the Hilton Rotterdam. TAmiRNA will also be a scientific contributor to the conference with a poster presentation on how to leverage extracellular vesicle microRNA cargo to enable in-vivo tracing of EVs based on their unique cargoes (biodistribution). Reach out to Matthias and Marianne directly to meet and discuss our latest developments and how TAmiRNA's  services can assist your business! TAmiRNA CEO Dr. Matthias Hackl